Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs

Abstract 4498: Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials

(2011) charles F. Voliva et al.   CANCER RESEARCH

Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1

(2010) Ayaz Najafov et al.   BIOCHEMICAL JOURNAL

Phosphatidylinositol 3-kinase-  inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

(2010) S. E. M. Herman et al.   BLOOD

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

(2010) Jean-Yves Pierga et al.   BREAST CANCER RESEARCH AND TREATMENT

Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis

(2010) J. H. Dey et al.   CANCER RESEARCH

Mammalian Target of Rapamycin Activator RHEB Is Frequently Overexpressed in Human Carcinomas and Is Critical and Sufficient for Skin Epithelial Carcinogenesis

(2010) Z. H. Lu et al.   CANCER RESEARCH

Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia

(2010) I. M. Ghobrial et al.   CLINICAL CANCER RESEARCH

Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39

(2010) Dexin Kong et al.   EUROPEAN JOURNAL OF CANCER

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

(2010) T E Witzig et al.   LEUKEMIA

The emerging mechanisms of isoform-specific PI3K signalling

(2010) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Insulin resistance is associated with the pathology of Alzheimer disease: The Hisayama Study

(2010) T. Matsuzaki et al.   NEUROLOGY

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

(2010) C A Sparks et al.   ONCOGENE

Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design

(2010) Hengmiao Cheng et al.   MedChemComm

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

(2010) Steven D. Knight et al.   ACS Medicinal Chemistry Letters

Effect of ZSTK474, a Novel Phosphatidylinositol 3-Kinase Inhibitor, on DNA-Dependent Protein Kinase

(2009) Dexin Kong et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers

(2009) S. Wee et al.   CANCER RESEARCH

Emerging common themes in regulation of PIKKs and PI3Ks

(2009) Harri Lempiäinen et al.   EMBO JOURNAL

Molecular alterations inAKT1,AKT2andAKT3detected in breast and prostatic cancer by FISH

(2009) Tove Kirkegaard et al.   HISTOPATHOLOGY

Specific Activation of mTORC1 by Rheb G-proteinin VitroInvolves Enhanced Recruitment of Its Substrate Protein

(2009) Tatsuhiro Sato et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

(2009) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

(2009) F. I. Raynaud et al.   MOLECULAR CANCER THERAPEUTICS

AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K

(2009) J M Askham et al.   ONCOGENE

Effects of PI3K inhibition and low docosahexaenoic acid on cognition and behavior

(2009) Sathyajit S. Bandaru et al.   PHYSIOLOGY & BEHAVIOR

Absence of AKT1 Mutations in Glioblastoma

(2009) Fonnet E. Bleeker et al.   PLoS One

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells

(2008) E. Weisberg et al.   BLOOD

Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias

(2008) M S Kim et al.   BRITISH JOURNAL OF CANCER

Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging

(2008) C. R. Schnell et al.   CANCER RESEARCH

Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

(2008) N. Rhodes et al.   CANCER RESEARCH

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2008) K. Stemke-Hale et al.   CANCER RESEARCH

Tumorigenic activity and therapeutic inhibition of Rheb GTPase

(2008) K. J. Mavrakis et al.   GENES & DEVELOPMENT

Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events

(2008) C. Nardella et al.   GENES & DEVELOPMENT

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy

(2008) Zhong Wang et al.   NATURE

Structure/function relationships underlying regulation of FOXO transcription factors

(2008) T Obsil et al.   ONCOGENE